Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
MET+
Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?
Answer from: Medical Oncologist at Academic Institution
Not at present and nothing is FDA approved or NCCN guidelines. Second line or later yes, especially on a trial
Comments
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Agree that currently no FDA approved agents upfron...
1337
Sign In
or
Register
to read more
5124
Related Questions
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Does anyone have experience obtaining sunvozertinib in the second-line setting for patients with EGFR exon 20 insertion mutations?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
How would you respond to a patient with early-stage resectable NSCLC who has a clinical complete response to neoadjuvant chemo-IO, but subsequently declines surgery, not feeling it's necessary anymore?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
Agree that currently no FDA approved agents upfron...